^
Association details:
| Biomarker: | STRN-ALK fusion + MET amplification |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Alecensa (alectinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review
Published date:
09/19/2021
Excerpt:
Herein, two advanced NSCLC patients received first-line alectinib treatment, given their positive ALK fusion status as determined by immunohistochemistry (IHC) testing results. Patients showed limited clinical response (PFS: 4 months) and primary resistance to alectinib respectively. Molecular profiling using next-generation sequencing (NGS) further revealed a striatin (STRN)-ALK fusion in the first patient accompanied by MET amplification, and a LIM domain only protein 7 (LMO7)-ALK fusion in another patient without any other known oncogenic alterations.
DOI:
https://doi.org/10.1111/jcmm.16897
